HIV

Virology

Classification

HIV is a member of the genus Lentivirus, part of the family Retroviridae. Lentiviruses have many morphologies and biological properties in common. Many species are infected by lentiviruses, which are characteristically responsible for long-duration illnesses with a long incubation period. Lentiviruses are transmitted as single-stranded, positive-sense, enveloped RNA viruses. Upon entry into the target cell, the viral RNA genome is converted (reverse transcribed) into double-stranded DNA by a virally encoded enzyme, reverse transcriptase, that is transported along with the viral genome in the virus particle. The resulting viral DNA is then imported into the cell nucleus and integrated into the cellular DNA by a virally encoded enzyme, integrase, and host co-factors. Once integrated, the virus may become latent, allowing the virus and its host cell to avoid detection by the immune system, for an indeterminate amount of time. The virus can remain dormant in the human body for up to ten years after primary infection; during this period the virus does not cause symptoms. Alternatively, the integrated viral DNA may be transcribed, producing new RNA genomes and viral proteins, using host cell resources, that are packaged and released from the cell as new virus particles that will begin the replication cycle anew.

Two types of HIV have been characterized: HIV-1 and HIV-2. HIV-1 is the virus that was initially discovered and termed both lymphadenopathy associated virus (LAV) and human T-lymphotropic virus 3 (HTLV-III). HIV-1 is more virulent and more infective than HIV-2, and is the cause of the majority of HIV infections globally. The lower infectivity of HIV-2, compared to HIV-1, implies that fewer of those exposed to HIV-2 will be infected per exposure. Due to its relatively poor capacity for transmission, HIV-2 is largely confined to West Africa.

Both HIV-1 and HIV-2 have gained an additional classification according to the International Committee on Taxonomy of Viruses, with the change being approved in 2020, to belong to the species called "Lentivirus humimdef1" and "Lentivirus humimdef2" for HIV-1 and HIV-2 respectively.

Structure and genome

Main article: Structure and genome of HIV

HIV is similar in structure to other retroviruses. It is roughly spherical with a diameter of about 120 nm, around 100,000 times smaller in volume than a red blood cell. It is composed of two copies of positive-sense single-stranded RNA that codes for the virus' nine genes enclosed by a ovoidal capsid composed of 2,000 copies of the viral protein p24. The single-stranded RNA is tightly bound to nucleocapsid proteins, p7, and enzymes needed for the development of the virion such as reverse transcriptase, proteases, ribonuclease and integrase. A matrix composed of the viral protein p17 surrounds the capsid ensuring the integrity of the virion particle.

This is, in turn, surrounded by the viral envelope, that is composed of the lipid bilayer taken from the membrane of a human host cell when the newly formed virus particle buds from the cell. The viral envelope contains proteins from the host cell and relatively few copies of the HIV envelope protein, The envelope protein, encoded by the HIV env gene, allows the virus to attach to target cells and fuse the viral envelope with the target cell's membrane releasing the viral contents into the cell and initiating the infectious cycle.

As the sole viral protein on the surface of the virus, the envelope protein is a major target for HIV vaccine efforts. Over half of the mass of the trimeric envelope spike is N-linked glycans. The density is high as the glycans shield the underlying viral protein from neutralisation by antibodies. This is one of the most densely glycosylated molecules known and the density is sufficiently high to prevent the normal maturation process of glycans during biogenesis in the endoplasmic and Golgi apparatus. The majority of the glycans are therefore stalled as immature 'high-mannose' glycans not normally present on human glycoproteins that are secreted or present on a cell surface. The unusual processing and high density means that almost all broadly neutralising antibodies that have so far been identified (from a subset of patients that have been infected for many months to years) bind to, or are adapted to cope with, these envelope glycans.

The molecular structure of the viral spike has now been determined by X-ray crystallography and cryogenic electron microscopy. These advances in structural biology were made possible due to the development of stable recombinant forms of the viral spike by the introduction of an intersubunit disulphide bond and an isoleucine to proline mutation (radical replacement of an amino acid) in gp41. The so-called SOSIP trimers not only reproduce the antigenic properties of the native viral spike, but also display the same degree of immature glycans as presented on the native virus. Recombinant trimeric viral spikes are promising vaccine candidates as they display less non-neutralising epitopes than recombinant monomeric gp120, which act to suppress the immune response to target epitopes.

The RNA genome consists of at least seven structural landmarks (LTR, TAR, RRE, PE, SLIP, CRS, and INS), and nine genes (gag, pol, and env, tat, rev, nef, vif, vpr, vpu, and sometimes a tenth tev, which is a fusion of tat, env and rev), encoding 19 proteins. Three of these genes, gag, pol, and env, contain information needed to make the structural proteins for new virus particles. For example, env codes for a protein called gp160 that is cut in two by a cellular protease to form gp120 and gp41. The six remaining genes, tat, rev, nef, vif, vpr, and vpu (or vpx in the case of HIV-2), are regulatory genes for proteins that control the ability of HIV to infect cells, produce new copies of virus (replicate), or cause disease.

The two tat proteins (p16 and p14) are transcriptional transactivators for the LTR promoter acting by binding the TAR RNA element. The TAR may also be processed into microRNAs that regulate the apoptosis genes ERCC1 and IER3. The rev protein (p19) is involved in shuttling RNAs from the nucleus and the cytoplasm by binding to the RRE RNA element. The vif protein (p23) prevents the action of APOBEC3G (a cellular protein that deaminates cytidine to uridine in the single-stranded viral DNA and/or interferes with reverse transcription). The vpr protein (p14) arrests cell division at G2/M. The nef protein (p27) down-regulates CD4 (the major viral receptor), as well as the MHC class I and class II molecules.

Nef also interacts with SH3 domains. The vpu protein (p16) influences the release of new virus particles from infected cells. The ends of each strand of HIV RNA contain an RNA sequence called a long terminal repeat (LTR). Regions in the LTR act as switches to control production of new viruses and can be triggered by proteins from either HIV or the host cell. The Psi element is involved in viral genome packaging and recognized by gag and rev proteins. The SLIP element () is involved in the frameshift in the gag-pol reading frame required to make functional pol.

Tropism

Main article: HIV tropism

The term viral tropism refers to the cell types a virus infects. HIV can infect a variety of immune cells such as CD4+ T cells, macrophages, and microglial cells. HIV-1 entry to macrophages and CD4+ T cells is mediated through interaction of the virion envelope glycoproteins (gp120) with the CD4 molecule on the target cells' membrane and also with chemokine co-receptors.

Macrophage-tropic (M-tropic) strains of HIV-1, or non-syncytia-inducing strains (NSI; now called R5 viruses) use the β-chemokine receptor, CCR5, for entry and are thus able to replicate in both macrophages and CD4+ T cells. This CCR5 co-receptor is used by almost all primary HIV-1 isolates regardless of viral genetic subtype. Indeed, macrophages play a key role in several critical aspects of HIV infection. They appear to be the first cells infected by HIV and perhaps the source of HIV production when CD4+ cells become depleted in the patient. Macrophages and microglial cells are the cells infected by HIV in the central nervous system. In the tonsils and adenoids of HIV-infected patients, macrophages fuse into multinucleated giant cells that produce huge amounts of virus.

T-tropic strains of HIV-1, or syncytia-inducing strains (SI; now called X4 viruses) replicate in primary CD4+ T cells as well as in macrophages and use the α-chemokine receptor, CXCR4, for entry.

Dual-tropic HIV-1 strains are thought to be transitional strains of HIV-1 and thus are able to use both CCR5 and CXCR4 as co-receptors for viral entry.

The α-chemokine SDF-1, a ligand for CXCR4, suppresses replication of T-tropic HIV-1 isolates. It does this by down-regulating the expression of CXCR4 on the surface of HIV target cells. M-tropic HIV-1 isolates that use only the CCR5 receptor are termed R5; those that use only CXCR4 are termed X4, and those that use both, X4R5. However, the use of co-receptors alone does not explain viral tropism, as not all R5 viruses are able to use CCR5 on macrophages for a productive infection and HIV can also infect a subtype of myeloid dendritic cells, which probably constitute a reservoir that maintains infection when CD4+ T cell numbers have declined to extremely low levels.

Some people are resistant to certain strains of HIV. For example, people with the CCR5-Δ32 mutation are resistant to infection by the R5 virus, as the mutation leaves HIV unable to bind to this co-receptor, reducing its ability to infect target cells.

Sexual intercourse is the major mode of HIV transmission. Both X4 and R5 HIV are present in the seminal fluid, which enables the virus to be transmitted from a male to his sexual partner. The virions can then infect numerous cellular targets and disseminate into the whole organism. However, a selection process leads to a predominant transmission of the R5 virus through this pathway, hypothesized to be because some variants may more easily infect cells when entering the body, or because some variants replicate more efficiently after initial infection and become the dominant variant in blood. In patients infected with subtype B HIV-1, there is often a co-receptor switch in late-stage disease and T-tropic variants that can infect a variety of T cells through CXCR4. These variants then replicate more aggressively with heightened virulence that causes rapid T cell depletion, immune system collapse, and opportunistic infections that mark the advent of AIDS. HIV-positive patients acquire an enormously broad spectrum of opportunistic infections, which was particularly problematic prior to the onset of HAART therapies; however, the same infections are reported among HIV-infected patients examined post-mortem following the onset of antiretroviral therapies. Thus, during the course of infection, viral adaptation to the use of CXCR4 instead of CCR5 may be a key step in the progression to AIDS. A number of studies with subtype B-infected individuals have determined that between 40 and 50 percent of AIDS patients can harbour viruses of the SI and, it is presumed, the X4 phenotypes.

HIV-2 is much less pathogenic than HIV-1 and is restricted in its worldwide distribution to West Africa. The adoption of "accessory genes" by HIV-2 and its more promiscuous pattern of co-receptor usage (including CD4-independence) may assist the virus in its adaptation to avoid innate restriction factors present in host cells. Adaptation to use normal cellular machinery to enable transmission and productive infection has also aided the establishment of HIV-2 replication in humans. A survival strategy for any infectious agent is not to kill its host, but ultimately become a commensal organism. Having achieved a low pathogenicity, over time, variants that are more successful at transmission will be selected.

Replication cycle

Entry to the cell

The HIV virion enters macrophages and CD4+ T cells by the adsorption of glycoproteins on its surface to receptors on the target cell followed by fusion of the viral envelope with the target cell membrane and the release of the HIV capsid into the cell.

Entry to the cell begins through interaction of the trimeric envelope complex (gp160 spike) on the HIV viral envelope and both CD4 and a chemokine co-receptor (generally either CCR5 or CXCR4, but others are known to interact) on the target cell surface. The gp160 spike contains binding domains for both CD4 and chemokine receptors.

The first step in fusion involves the high-affinity attachment of the CD4 binding domains of gp120 to CD4. Once gp120 is bound with the CD4 protein, the envelope complex undergoes a structural change, exposing the chemokine receptor binding domains of gp120 and allowing them to interact with the target chemokine receptor. This allows for a more stable two-pronged attachment, which allows the N-terminal fusion peptide gp41 to penetrate the cell membrane. Repeat sequences in gp41, HR1, and HR2 then interact, causing the collapse of the extracellular portion of gp41 into a hairpin shape. This loop structure brings the virus and cell membranes close together, allowing fusion of the membranes and subsequent entry of the viral capsid.

HIV can infect dendritic cells (DCs) by this CD4-CCR5 route, but another route using mannose-specific C-type lectin receptors such as DC-SIGN can also be used. DCs are one of the first cells encountered by the virus during sexual transmission. They are currently thought to play an important role by transmitting HIV to T cells when the virus is captured in the mucosa by DCs.

HIV-1 entry, as well as entry of many other retroviruses, has long been believed to occur exclusively at the plasma membrane. More recently, however, productive infection by pH-independent, clathrin-mediated endocytosis of HIV-1 has also been reported and was recently suggested to constitute the only route of productive entry.

Replication and transcription

Shortly after the viral capsid enters the cell, an enzyme called reverse transcriptase liberates the positive-sense single-stranded RNA genome from the attached viral proteins and copies it into a complementary DNA (cDNA) molecule. The process of reverse transcription is extremely error-prone, and the resulting mutations may cause drug resistance or allow the virus to evade the body's immune system. The reverse transcriptase also has ribonuclease activity that degrades the viral RNA during the synthesis of cDNA, as well as DNA-dependent DNA polymerase activity that creates a sense DNA from the antisense cDNA. Together, the cDNA and its complement form a double-stranded viral DNA that is then transported into the cell nucleus. The integration of the viral DNA into the host cell's genome is carried out by another viral enzyme called integrase.

The integrated viral DNA may then lie dormant, in the latent stage of HIV infection. This means that those cells most likely to be targeted, entered and subsequently killed by HIV are those actively fighting infection.

During viral replication, the integrated DNA provirus is transcribed into RNA. The full-length genomic RNAs (gRNA) can be packaged into new viral particles in a pseudodiploid form. The selectivity in the packaging is explained by the structural properties of the dimeric conformer of the gRNA. The gRNA dimer is characterized by a tandem three-way junction within the gRNA monomer, in which the SD and AUG hairpins, responsible for splicing and translation respectively, are sequestered and the DIS (dimerization initiation signal) hairpin is exposed. The formation of the gRNA dimer is mediated by a 'kissing' interaction between the DIS hairpin loops of the gRNA monomers. At the same time, certain guanosine residues in the gRNA are made available for binding of the nucleocapsid (NC) protein leading to the subsequent virion assembly. The labile gRNA dimer has been also reported to achieve a more stable conformation following the NC binding, in which both the DIS and the U5:AUG regions of the gRNA participate in extensive base pairing.

RNA can also be processed to produce mature messenger RNAs (mRNAs). In most cases, this processing involves RNA splicing to produce mRNAs that are shorter than the full-length genome. Which part of the RNA is removed during RNA splicing determines which of the HIV protein-coding sequences is translated.

Mature HIV mRNAs are exported from the nucleus into the cytoplasm, where they are translated to produce HIV proteins, including Rev. As the newly produced Rev protein is produced it moves to the nucleus, where it binds to full-length, unspliced copies of virus RNAs and allows them to leave the nucleus. Some of these full-length RNAs function as mRNAs that are translated to produce the structural proteins Gag and Env. Gag proteins bind to copies of the virus RNA genome to package them into new virus particles. HIV-1 and HIV-2 appear to package their RNA differently. HIV-1 will bind to any appropriate RNA. HIV-2 will preferentially bind to the mRNA that was used to create the Gag protein itself.

Recombination

Two RNA genomes are encapsidated in each HIV-1 particle (see Structure and genome of HIV). Upon infection and replication catalyzed by reverse transcriptase, recombination between the two genomes can occur. Recombination occurs as the single-strand, positive-sense RNA genomes are reverse transcribed to form DNA. During reverse transcription, the nascent DNA can switch multiple times between the two copies of the viral RNA. This form of recombination is known as copy-choice. Recombination events may occur throughout the genome. Anywhere from two to 20 recombination events per genome may occur at each replication cycle, and these events can rapidly shuffle the genetic information that is transmitted from parental to progeny genomes.

Viral recombination produces genetic variation that likely contributes to the evolution of resistance to anti-retroviral therapy. Recombination may also contribute, in principle, to overcoming the immune defenses of the host. Yet, for the adaptive advantages of genetic variation to be realized, the two viral genomes packaged in individual infecting virus particles need to have arisen from separate progenitor parental viruses of differing genetic constitution. It is unknown how often such mixed packaging occurs under natural conditions.

Bonhoeffer et al. suggested that template switching by reverse transcriptase acts as a repair process to deal with breaks in the single-stranded RNA genome. In addition, Hu and Temin suggested that recombination is an adaptation for repair of damage in the RNA genomes. Strand switching (copy-choice recombination) by reverse transcriptase could generate an undamaged copy of genomic DNA from two damaged single-stranded RNA genome copies. This view of the adaptive benefit of recombination in HIV could explain why each HIV particle contains two complete genomes, rather than one. Furthermore, the view that recombination is a repair process implies that the benefit of repair can occur at each replication cycle, and that this benefit can be realized whether or not the two genomes differ genetically. On the view that recombination in HIV is a repair process, the generation of recombinational variation would be a consequence, but not the cause of, the evolution of template switching.

HIV-1 infection causes chronic inflammation and production of reactive oxygen species. Thus, the HIV genome may be vulnerable to oxidative damage, including breaks in the single-stranded RNA. For HIV, as well as for viruses in general, successful infection depends on overcoming host defense strategies that often include production of genome-damaging reactive oxygen species. Thus, Michod et al. suggested that recombination by viruses is an adaptation for repair of genome damage, and that recombinational variation is a byproduct that may provide a separate benefit.

Assembly and release

The final step of the viral cycle, assembly of new HIV-1 virions, begins at the plasma membrane of the host cell. The Env polyprotein (gp160) goes through the endoplasmic reticulum and is transported to the Golgi apparatus where it is cleaved by furin resulting in the two HIV envelope glycoproteins, gp41 and gp120. These are transported to the plasma membrane of the host cell where gp41 anchors gp120 to the membrane of the infected cell. The Gag (p55) and Gag-Pol (p160) polyproteins also associate with the inner surface of the plasma membrane along with the HIV genomic RNA as the forming virion begins to bud from the host cell. The budded virion is still immature as the gag polyproteins still need to be cleaved into the actual matrix, capsid and nucleocapsid proteins. This cleavage is mediated by the packaged viral protease and can be inhibited by antiretroviral drugs of the protease inhibitor class. The various structural components then assemble to produce a mature HIV virion. Only mature virions are then able to infect another cell.

Spread within the body

The classical process of infection of a cell by a virion can be called "cell-free spread" to distinguish it from a more recently recognized process called "cell-to-cell spread". In cell-free spread (see figure), virus particles bud from an infected T cell, enter the blood or extracellular fluid and then infect another T cell following a chance encounter. HIV can also disseminate by direct transmission from one cell to another by a process of cell-to-cell spread, for which two pathways have been described. Firstly, an infected T cell can transmit virus directly to a target T cell via a virological synapse. Secondly, an antigen-presenting cell (APC), such as a macrophage or dendritic cell, can transmit HIV to T cells by a process that either involves productive infection (in the case of macrophages) or capture and transfer of virions in trans (in the case of dendritic cells). Whichever pathway is used, infection by cell-to-cell transfer is reported to be much more efficient than cell-free virus spread. A number of factors contribute to this increased efficiency, including polarised virus budding towards the site of cell-to-cell contact, close apposition of cells, which minimizes fluid-phase diffusion of virions, and clustering of HIV entry receptors on the target cell towards the contact zone. Cell-to-cell spread is thought to be particularly important in lymphoid tissues, where CD4+ T cells are densely packed and likely to interact frequently. Intravital imaging studies have supported the concept of the HIV virological synapse in vivo. The many dissemination mechanisms available to HIV contribute to the virus' ongoing replication in spite of anti-retroviral therapies.

Genetic variability

HIV differs from many viruses in that it has very high genetic variability. This diversity is a result of its fast replication cycle, with the generation of about 1010 virions every day, coupled with a high mutation rate of approximately 3 x 10−5 per nucleotide base per cycle of replication and recombinogenic properties of reverse transcriptase. Some estimates put HIV's mutation rate as high as 4.1 x 10−3 substitutions per base pair, making HIV the microbe with the highest mutation rate known by far. A 2014 study estimated that about 15−20% of all HIV mutations are due to recombination, numbering roughly 1.35 x 10−3 recombination events per nucleotide (REPN) per replication cycle.

This complex scenario leads to the generation of many variants of HIV in a single infected patient in the course of one day. This variability is compounded when a single cell is simultaneously infected by two or more different strains of HIV. When simultaneous infection occurs, the genome of progeny virions may be composed of RNA strands from two different strains. This hybrid virion then infects a new cell where it undergoes replication. As this happens, the reverse transcriptase, by jumping back and forth between the two different RNA templates, will generate a newly synthesized retroviral DNA sequence that is a recombinant between the two parental genomes. This recombination is most obvious when it occurs between subtypes.

The closely related simian immunodeficiency virus (SIV) has evolved into many strains, classified by the natural host species. SIV strains of the African green monkey (SIVagm) and sooty mangabey (SIVsmm) are thought to have a long evolutionary history with their hosts. These hosts have adapted to the presence of the virus, which is present at high levels in the host's blood, but evokes only a mild immune response, does not cause the development of simian AIDS, and does not undergo the extensive mutation and recombination typical of HIV infection in humans.

In contrast, when these strains infect species that have not adapted to SIV ("heterologous" or similar hosts such as rhesus or cynomologus macaques), the animals develop AIDS and the virus generates genetic diversity similar to what is seen in human HIV infection. Chimpanzee SIV (SIVcpz), the closest genetic relative of HIV-1, is associated with increased mortality and AIDS-like symptoms in its natural host. SIVcpz appears to have been transmitted relatively recently to chimpanzee and human populations, so their hosts have not yet adapted to the virus.

Three groups of HIV-1 have been identified on the basis of differences in the envelope (env) region: M, N, and O. Group M is the most prevalent and is subdivided into eight subtypes (or clades), based on the whole genome, which are geographically distinct. The most prevalent are subtypes B (found mainly in North America and Europe), A and D (found mainly in Africa), and C (found mainly in Africa and Asia); these subtypes form branches in the phylogenetic tree representing the lineage of the M group of HIV-1. Co-infection with distinct subtypes gives rise to circulating recombinant forms (CRFs). In 2000, the last year in which an analysis of global subtype prevalence was made, 47.2% of infections worldwide were of subtype C, 26.7% were of subtype A/CRF02_AG, 12.3% were of subtype B, 5.3% were of subtype D, 3.2% were of CRF_AE, and the remaining 5.3% were composed of other subtypes and CRFs. Most HIV-1 research is focused on subtype B; few laboratories focus on the other subtypes. The existence of a fourth group, "P", has been hypothesised based on a virus isolated in 2009. The strain is apparently derived from gorilla SIV (SIVgor), first isolated from western lowland gorillas in 2006.

HIV-2's closest relative is SIVsm, a strain of SIV found in sooty mangabees. Since HIV-1 is derived from SIVcpz, and HIV-2 from SIVsm, the genetic sequence of HIV-2 is only partially homologous to HIV-1 and more closely resembles that of SIVsm.

Diagnosis

Main article: Diagnosis of HIV/AIDS

Many HIV-positive people are unaware that they are infected with the virus.

For example, in 2001 less than 1% of the sexually active urban population in Africa had been tested, and this proportion is even lower in rural populations. Furthermore, in 2001 only 0.5% of pregnant women attending urban health facilities were counselled, tested or received their test results. Again, this proportion is even lower in rural health facilities. Since donors may therefore be unaware of their infection, donor blood and blood products used in medicine and medical research are routinely screened for HIV.

HIV-1 testing is initially done using an enzyme-linked immunosorbent assay (ELISA) to detect antibodies to HIV-1. Specimens with a non-reactive result from the initial ELISA are considered HIV-negative, unless new exposure to an infected partner or partner of unknown HIV status has occurred. Specimens with a reactive ELISA result are retested in duplicate. If the result of either duplicate test is reactive, the specimen is reported as repeatedly reactive and undergoes confirmatory testing with a more specific supplemental test (e.g., a polymerase chain reaction (PCR), western blot or, less commonly, an immunofluorescence assay (IFA)). Only specimens that are repeatedly reactive by ELISA and positive by IFA or PCR or reactive by western blot are considered HIV-positive and indicative of HIV infection. Specimens that are repeatedly ELISA-reactive occasionally provide an indeterminate western blot result, which may be either an incomplete antibody response to HIV in an infected person or nonspecific reactions in an uninfected person.

Although IFA can be used to confirm infection in these ambiguous cases, this assay is not widely used. In general, a second specimen should be collected more than a month later and retested for persons with indeterminate western blot results. Although much less commonly available, nucleic acid testing (e.g., viral RNA or proviral DNA amplification method) can also help diagnosis in certain situations. In addition, a few tested specimens might provide inconclusive results because of a low quantity specimen. In these situations, a second specimen is collected and tested for HIV infection.

Modern HIV testing is extremely accurate, when the window period is taken into consideration. A single screening test is correct more than 99% of the time. The chance of a false-positive result in a standard two-step testing protocol is estimated to be about 1 in 250,000 in a low risk population. Testing post-exposure is recommended immediately and then at six weeks, three months, and six months.

The latest recommendations of the US Centers for Disease Control and Prevention (CDC) show that HIV testing must start with an immunoassay combination test for HIV-1 and HIV-2 antibodies and p24 antigen. A negative result rules out HIV exposure, while a positive one must be followed by an HIV-1/2 antibody differentiation immunoassay to detect which antibodies are present. This gives rise to four possible scenarios:

• 1. HIV-1 (+) & HIV-2 (−): HIV-1 antibodies detected
• 2. HIV-1 (−) & HIV-2 (+): HIV-2 antibodies detected
• 3. HIV-1 (+) & HIV-2 (+): both HIV-1 and HIV-2 antibodies detected
• 4. HIV-1 (−) or indeterminate & HIV-2 (−): Nucleic acid test must be carried out to detect the acute infection of HIV-1 or its absence.

Research

Main article: HIV/AIDS research

HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.

Many governments and research institutions participate in HIV/AIDS research. This research includes behavioral health interventions, such as research into sex education, and drug development, such as research into microbicides for sexually transmitted diseases, HIV vaccines, and anti-retroviral drugs. Other medical research areas include the topics of pre-exposure prophylaxis, post-exposure prophylaxis, circumcision, and accelerated aging effects.

Treatment and transmission

Main article: Management of HIV/AIDS

The management of HIV/AIDS typically involves the use of multiple antiretroviral drugs. In many parts of the world, HIV has become a chronic condition, with progression to AIDS increasingly rare. HIV has an estimated basic reproduction number (R_0) of 2–5, meaning that the average person with HIV typically infects about 2–5 other people.

HIV latency and the resulting viral reservoir in CD4+ T cells, dendritic cells, and macrophages is the main barrier to eradication of the virus.

While HIV is highly virulent, transmission through sexual contact does not occur when an HIV-positive individual maintains a consistently undetectable viral load (

Studies that established the U=U principle include Opposites Attract, PARTNER 1, PARTNER 2 (which focused on male-male couples), and HPTN052 (which focused on heterosexual couples). These studies involved couples where one partner was HIV-positive and one was HIV-negative, and included regular HIV testing. Across these four studies, a total of 4,097 couples participated from four continents, reporting 151,880 acts of condomless sex with zero phylogenetically-linked HIV transmissions when the positive partner had an undetectable viral load. Following these findings, the U=U consensus statement advocating the use of the term 'zero risk' was endorsed by numerous individuals and organizations, including the CDC, the British HIV Association, and The Lancet medical journal.

Additionally, reactivation of herpes simplex virus-2 (HSV-2) in individuals with genital herpes is associated with an increase in CCR-5 enriched CD4+ T cells and inflammatory dendritic cells in the dermis of ulcerated genital skin, persisting even after ulcer healing. HIV's tropism for CCR-5 positive cells contributes to the two- to threefold increased risk of HIV acquisition in persons with genital herpes. Notably, daily antiviral medication, such as acyclovir, does not reduce the subclinical post-reactivation inflammation and therefore does not decrease the risk of HIV acquisition.

History

Main article: History of HIV/AIDS

Origins

Both HIV-1 and HIV-2 are believed to have originated in non-human primates in West-central Africa, and are believed to have transferred to humans (a process known as zoonosis) in the early 20th century.

HIV-1 appears to have originated in southern Cameroon through the evolution of SIVcpz, a simian immunodeficiency virus (SIV) that infects wild chimpanzees (HIV-1 descends from the SIVcpz endemic in the chimpanzee subspecies Pan troglodytes troglodytes). The closest relative of HIV-2 is SIVsmm, a virus of the sooty mangabey (Cercocebus atys atys), an Old World monkey living in littoral West Africa (from southern Senegal to western Côte d'Ivoire).

HIV-1 is thought to have jumped the species barrier on at least three separate occasions, giving rise to the three groups of the virus, M, N, and O.

There is evidence that humans who participate in bushmeat activities, either as hunters or as bushmeat vendors, commonly acquire SIV. However, SIV is a weak virus, and it is typically suppressed by the human immune system within weeks of infection. It is thought that several transmissions of the virus from individual to individual in quick succession are necessary to allow it enough time to mutate into HIV. Furthermore, due to its relatively low person-to-person transmission rate, it can only spread throughout the population in the presence of one or more high-risk transmission channels, which are thought to have been absent in Africa prior to the 20th century.

Specific proposed high-risk transmission channels, allowing the virus to adapt to humans and spread throughout the society, depend on the proposed timing of the animal-to-human crossing. Genetic studies of the virus suggest that the most recent common ancestor of the HIV-1 M group dates back to . Proponents of this dating link the HIV epidemic with the emergence of colonialism and growth of large colonial African cities, leading to social changes, including different patterns of sexual contact (especially multiple, concurrent partnerships), the spread of sex work, and the concomitant high frequency of genital ulcer diseases (such as syphilis) in nascent colonial cities. While transmission rates of HIV during vaginal intercourse are typically low, they are increased manyfold if one of the partners has a sexually transmitted infection resulting in genital ulcers. Early 1900s colonial cities were notable for their high prevalence of sex work and genital ulcers to the degree that as of 1928 as many as 45% of female residents of eastern Leopoldville (currently Kinshasa) were thought to have been involved with sex work and as of 1933 around 15% of all residents of the same city were infected by one of the forms of syphilis.

The earliest, well-documented case of HIV in a human dates back to 1959 in the Belgian Congo. The virus may have been present in the United States as early as the mid- to late 1960s, as a sixteen-year-old male named Robert Rayford presented with symptoms in 1966 and died in 1969.

An alternative and likely complementary hypothesis points to the widespread use of unsafe medical practices in Africa during years following World War II, such as unsterile reuse of single-use syringes during mass vaccination, antibiotic, and anti-malaria treatment campaigns. Research on the timing of most recent common ancestor for HIV-1 groups M and O, as well as on HIV-2 groups A and B, indicates that SIV has given rise to transmissible HIV lineages throughout the twentieth century. The dispersed timing of these transmissions to humans implies that no single external factor is needed to explain the cross-species transmission of HIV. This observation is consistent with both of the two prevailing views of the origin of the HIV epidemics, namely SIV transmission to humans during the slaughter or butchering of infected primates, and the colonial expansion of sub-Saharan African cities.

Discovery

The first news story on "an exotic new disease" appeared May 18, 1981, in the gay newspaper New York Native.

AIDS was first clinically observed in 1981 in the United States. The initial cases were a cluster of injection drug users and gay men with no known cause of impaired immunity who showed symptoms of Pneumocystis pneumonia (PCP or PJP, the latter term recognizing that the causative agent is now called Pneumocystis jirovecii), a rare opportunistic infection that was known to occur in people with very compromised immune systems. Soon thereafter, researchers at the NYU School of Medicine studied gay men developing a previously rare skin cancer called Kaposi's sarcoma (KS). Many more cases of PJP and KS emerged, alerting U.S. Centers for Disease Control and Prevention (CDC) and a CDC task force was formed to monitor the outbreak. The earliest retrospectively described case of AIDS is believed to have been in Norway beginning in 1966.

In the beginning, the CDC did not have an official name for the disease, often referring to it by way of the diseases that were associated with it, for example, lymphadenopathy, the disease after which the discoverers of HIV originally named the virus. They also used Kaposi's Sarcoma and Opportunistic Infections, the name by which a task force had been set up in 1981. In the general press, the term GRID, which stood for gay-related immune deficiency, had been coined. The CDC, in search of a name and looking at the infected communities, coined "the 4H disease", as it seemed to single out homosexuals, heroin users, hemophiliacs, and Haitians. However, after determining that AIDS was not isolated to the gay community, By September 1982 the CDC started using the name AIDS.

In 1983, two separate research groups led by American Robert Gallo and French investigators Françoise Barré-Sinoussi and Luc Montagnier independently declared that a novel retrovirus may have been infecting AIDS patients, and published their findings in the same issue of the journal Science. Gallo claimed that a virus his group had isolated from a person with AIDS was strikingly similar in shape to other human T-lymphotropic viruses (HTLVs) his group had been the first to isolate. Gallo admitted in 1987 that the virus he claimed to have discovered in 1984 was in reality a virus sent to him from France the year before. Gallo's group called their newly isolated virus HTLV-III. Montagnier's group isolated a virus from a patient presenting with swelling of the lymph nodes of the neck and physical weakness, two classic symptoms of primary HIV infection. Contradicting the report from Gallo's group, Montagnier and his colleagues showed that core proteins of this virus were immunologically different from those of HTLV-I. Montagnier's group named their isolated virus lymphadenopathy-associated virus (LAV). As these two viruses turned out to be the same, in 1986 LAV and HTLV-III were renamed HIV.

Another group working contemporaneously with the Montagnier and Gallo groups was that of Jay A. Levy at the University of California, San Francisco. He independently discovered the AIDS virus in 1983 and named it the AIDS associated retrovirus (ARV). This virus was very different from the virus reported by the Montagnier and Gallo groups. The ARV strains indicated, for the first time, the heterogeneity of HIV isolates and several of these remain classic examples of the AIDS virus found in the United States.

References

References

1. Padilla-Sanchez, Victor. (2026-01-17). "HIV Infection at Atomic Resolution".
2. (May 1993). "How does HIV cause AIDS?". Science.
3. (2009). "Emerging Concepts in the Immunopathogenesis of AIDS". Annual Review of Medicine.
4. (2016). "Opportunistic Infections in HIV-Infected Patients Differ Strongly in Frequencies and Spectra between Patients with Low CD4+ Cell Counts Examined Postmortem and Compensated Patients Examined Antemortem Irrespective of the HAART Era". PLOS ONE.
5. (December 2007). "2007 AIDS epidemic update".
6. (June 2019). "Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study". Lancet.
7. (February 2019). "HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable". JAMA.
8. (2012). "HIV-Specific Antibodies Capable of ADCC Are Common in Breastmilk and Are Associated with Reduced Risk of Transmission in Women with High Viral Loads". PLOS Pathogens.
9. (2009). "Anthropology and public health : bridging differences in culture and society". Oxford University Press.
10. Mead MN. (2008). "Contaminants in human milk: weighing the risks against the benefits of breastfeeding". Environmental Health Perspectives.
11. (2017-05-15). "Preventing Mother-to-Child Transmission of HIV".
12. (August 2010). "Manipulation of dendritic cell function by viruses". Current Opinion in Microbiology.
13. (January 2014). "Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection". Nature.
14. (November 2012). "HIV-1 induced bystander apoptosis". Viruses.
15. (2012). "Robbins Basic Pathology". Elsevier Health Sciences.
16. International Committee on Taxonomy of Viruses. (2002). "61.0.6. Lentivirus". [[National Institutes of Health]].
17. International Committee on Taxonomy of Viruses. (2002). "61. Retroviridae". National Institutes of Health.
18. (November 1993). "HIV pathogenesis and long-term survival". AIDS.
19. (May 2006). "Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses". ACS Chemical Biology.
20. (September 2011). "HIV latency". Cold Spring Harbor Perspectives in Medicine.
21. (February 28, 2003). "Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal". Statistics in Medicine.
22. (2002). "Human Immunodeficiency Virus Type 2". [[Journal of General Virology]].
23. "Genus: Lentivirus {{!}} ICTV".
24. (2002). "A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening". Journal of Medicinal Chemistry.
25. (2007). "Lippincott's Illustrated Reviews: Microbiology". Lippincott Williams & Wilkins.
26. Various. (2008). "HIV Sequence Compendium 2008 Introduction".
27. (April 1997). "Core structure of gp41 from the HIV envelope glycoprotein". Cell.
28. (May 2010). "Few and far between: how HIV may be evading antibody avidity". PLOS Pathogens.
29. National Institute of Health. (June 17, 1998). "Crystal structure of key HIV protein reveals new prevention, treatment targets".
30. (March 2016). "Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein". Cell Reports.
31. (June 2015). "Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies". Nature Communications.
32. (September 2015). "Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope". Journal of Virology.
33. (April 2015). "Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design". Current Opinion in Virology.
34. (December 2013). "Crystal structure of a soluble cleaved HIV-1 envelope trimer". Science.
35. (December 2013). "Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer". Science.
36. (September 2013). "A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies". PLOS Pathogens.
37. (June 2015). "Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers". Cell Reports.
38. (December 2015). "Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes". Cell.
39. (April 2008). "Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element". Nucleic Acids Research.
40. (2009). "HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression". Retrovirology.
41. (Nov 2013). "Structural features of antiviral DNA cytidine deaminases". [[Biological Chemistry (journal).
42. (April 1991). "Serine phosphorylation-independent downregulation of cell-surface CD4 by nef". Nature.
43. (March 1996). "Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein". Nature Medicine.
44. (October 2001). "HIV-1 Nef impairs MHC class II antigen presentation and surface expression". Proceedings of the National Academy of Sciences of the United States of America.
45. (March 2012). "The HIV-1 env protein: a coat of many colors". Current HIV/AIDS Reports.
46. (1998). "A new classification for HIV-1". Nature.
47. (2005). "Assessing ch vbgemokine co-receptor usage in HIV". Current Opinion in Infectious Diseases.
48. (1990). "HIV I infection of dendritic cells". [[International Review of Immunology]].
49. (2003). "The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy". AIDS.
50. (1993). "Genotypic and phenotypic characterization of HIV-1 patients with primary infection". Science.
51. (1994). "Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission". Journal of Clinical Investigation.
52. (1996). "Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission". Journal of Virology.
53. (2005). "The X4 phenotype of HIV type 1 evolves from R5 in two children of mothers, carrying X4, and is not linked to transmission". AIDS Research and Human Retroviruses.
54. (1997). "Coreceptors: implications for HIV pathogenesis and therapy". Science.
55. (1994). "MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance". The Journal of Infectious Diseases.
56. (1996). "Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection". The Journal of Infectious Diseases.
57. (December 2017). "Lentiviruses and Macrophages: Molecular and Cellular Interactions". [[Caister Academic Press]].
58. (1998). "HIV entry and its inhibition". Cell.
59. (1998). "The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens". Science.
60. (2008). "HIV-1 envelope protein binds to and signals through integrin alpha(4)beta(7), the gut mucosal homing receptor for peripheral T cells". Nature Immunology.
61. (2003). "Transmission, acute HIV-1 infection and the quest for strategies to prevent infection". Nature Medicine.
62. (Aug 2009). "The brain-specific factor FEZ1 is a determinant of neuronal susceptibility to HIV-1 infection". Proceedings of the National Academy of Sciences.
63. (2005). "Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry". Journal of Virology.
64. (2009). "HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes". Cell.
65. (2009). "Visualizing fusion of pseudotyped HIV-1 particles in real time by live cell microscopy". Retrovirology.
66. (2010). "Mechanisms of viral entry: sneaking in the front door". Protoplasma.
67. (2010). "Endocytosis of HIV: anything goes". Trends in Microbiology.
68. (2005). "Newly identified host factors modulate HIV replication". Immunology Letters.
69. (January 2008). "IV. Viruses> F. Animal Virus Life Cycles > 3. The Life Cycle of HIV". Community College of Baltimore County.
70. (2001). "Hostile takeovers: viral appropriation of the NF-kB pathway". Journal of Clinical Investigation.
71. (2015-05-22). "Structure of the HIV-1 RNA packaging signal". Science.
72. (2016-10-10). "NMR detection of intermolecular interaction sites in the dimeric 5′-leader of the HIV-1 genome". Proceedings of the National Academy of Sciences.
73. (November 2012). "Dynamic regulation of HIV-1 mRNA populations analyzed by single-molecule enrichment and long-read sequencing". Nucleic Acids Research.
74. (1998). "The HIV-1 Rev protein". Annual Review of Microbiology.
75. (April 2002). "Destiny of unspliced retroviral RNA: ribosome and/or virion?". Journal of Virology.
76. (July 2016). "Coordination of Genomic RNA Packaging with Viral Assembly in HIV-1". Viruses.
77. (March 2012). "Different effects of the TAR structure on HIV-1 and HIV-2 genomic RNA translation". Nucleic Acids Research.
78. (2015-07-28). "Role of Lipids in Virus Assembly". Frontiers Media SA.
79. (July 2008). "In vitro expression of the HIV-2 genomic RNA is controlled by three distinct internal ribosome entry segments that are regulated by the HIV protease and the Gag polyprotein". RNA.
80. (1990). "Retroviral recombination and reverse transcription". Science.
81. (2006). "Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients". Journal of Virology.
82. (2007). "Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment". Journal of Virology.
83. (2006). "High frequency of genetic recombination is a common feature of primate lentivirus replication". Journal of Virology.
84. (2004). "Evidence for positive epistasis in HIV-1". Science.
85. (1997). "Oxidative stress in human immunodeficiency virus infection". Cellular and Molecular Life Sciences.
86. (May 2008). "Adaptive value of sex in microbial pathogens". Infection, Genetics and Evolution.
87. (November 26, 1992). "Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160". Nature.
88. Gelderblom HR. (1997). "HIV sequence compendium". [[Los Alamos National Laboratory]].
89. (2015). "Hybrid Spreading Mechanisms and T Cell Activation Shape the Dynamics of HIV-1 Infection". PLOS Computational Biology.
90. (2004). "HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse". Journal of Experimental Medicine.
91. (2008). "Avoiding the void: cell-to-cell spread of human viruses". Nature Reviews Microbiology.
92. (2013). "High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy". AIDS.
93. (2012). "In vivo imaging of virological synapses". Nature Communications.
94. (2011). "Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy". Nature.
95. (1995). "Recombination in AIDS viruses". Journal of Molecular Evolution.
96. (January 2004). "The causes and consequences of HIV evolution". Nature Reviews Genetics.
97. (October 2008). "Estimating drug efficacy and viral dynamic parameters: HIV and HCV". Statistics in Medicine.
98. (28 April 2017). "Recent advances in understanding HIV evolution". [[F1000 (publisher).
99. (1 April 2014). "Fifteen to Twenty Percent of HIV Substitution Mutations Are Associated with Recombination". [[American Society for Microbiology]].
100. (2009). "Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts". Nature Medicine.
101. (2001). "High virus loads in naturally and experimentally SIVagm-infected African green monkeys". Virology.
102. (1996). "Why don't the natural hosts of SIV develop simian AIDS?". The Journal of NIH Research.
103. (1991). "Development of vivo of genetic variability of simian immunodeficiency virus". Proceedings of the National Academy of Sciences of the United States of America.
104. (1984). "A new type D retrovirus isolated from macaques with an immunodeficiency syndrome". Science.
105. (2009). "Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz". Nature.
106. (2006). "Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1". Cell.
107. (2002). "Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy". The Lancet Infectious Diseases.
108. (1998). "HIV sequence compendium". [[Los Alamos National Laboratory]].
109. (2002). "Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000". Journal of Acquired Immune Deficiency Syndromes.
110. (2003). "Travel and the spread of HIV-1 genetic variants". The Lancet Infectious Diseases.
111. (August 2009). "A new human immunodeficiency virus derived from gorillas". Nature Medicine.
112. Smith, Lewis. (August 3, 2009). "Woman found carrying new strain of HIV from gorillas".
113. (August 2010). "The evolution of HIV-1 and the origin of AIDS". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.
114. (July 2006). "Chimpanzee reservoirs of pandemic and nonpandemic HIV-1". Science.
115. Kleinman S. (September 2004). "Patient information: Blood donation and transfusion". Uptodate.
116. Centers for Disease Control and Prevention. (2001). "Revised guidelines for HIV counseling, testing, and referral". MMWR Recommendations and Reports.
117. (1991). "Indeterminate human immunodeficiency virus type 1 western blots: seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation". The Journal of Infectious Diseases.
118. "Country Comparison :: HIV/AIDS - Deaths". The World Factbook, Central Intelligence Agency.
119. (November 2012). "Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation". Annals of Internal Medicine.
120. (July 2005). "Screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force". Annals of Internal Medicine.
121. (July 2010). "Postexposure prophylaxis against human immunodeficiency virus". American Family Physician.
122. (June 27, 2014). "Quick Reference Guide—Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations". New York State Department of Health.
123. "HIV Treatment: FDA-Approved HIV Medicines". AIDSinfo.
124. (January 30, 2020). "Playing the Numbers Game: R0". National Emerging Special Pathogen Training and Education Center.
125. (29 September 2021). "The Current Status of Latency Reversing Agents for HIV-1 Remission". Annual Review of Virology.
126. Swiss National AIDS Commission. (15 October 2016). "The Swiss statement". [[HIV i-Base]].
127. (29 January 2016). "HIV is not transmitted under fully suppressive therapy: The Swiss Statement—eight years later". [[Swiss Medical Weekly]].
128. The Lancet HIV. (November 2017). "U=U taking off in 2017". The Lancet. HIV.
129. (2019). "Can't Pass It On". [[Terrence Higgins Trust]].
130. (August 2018). "Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study". The Lancet. HIV.
131. (July 2016). "Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy". JAMA.
132. Rodger, A. (for the PARTNER study group). (July 2018). "Risk of HIV transmission through condomless sex in MSM couples with suppressive ART: The PARTNER2 Study extended results in gay men".
133. (10 January 2019). "The science is clear: with HIV, undetectable equals untransmittable". [[National Institutes of Health]].
134. (September 2016). "Antiretroviral Therapy for the Prevention of HIV-1 Transmission". The New England Journal of Medicine.
135. (17 November 2017). "U=U: Talking to patients about transmission risk".
136. (21 July 2016). "Consensus statement: Risk of Sexual Transmission of HIV from a Person Living with HIV who has an Undetectable Viral Load". [[Prevention Access Campaign]].
137. (August 2009). "Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition". Nature Medicine.
138. (December 2017). "Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis". The Lancet. Infectious Diseases.
139. (2011). "Origins of HIV and the AIDS Pandemic". Cold Spring Harbor Perspectives in Medicine.
140. (2014). "The early spread and epidemic ignition of HIV-1 in human populations". Science.
141. (1999). "Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes". Nature.
142. (2006). "Chimpanzee reservoirs of pandemic and nonpandemic HIV-1". Science.
143. (2008). "Retrotransposons revisited: the restraint and rehabilitation of parasites". Cell.
144. (2001). "The origins of acquired immune deficiency syndrome viruses: where and when?". Philosophical Transactions of the Royal Society B.
145. (2005). "Central African hunters exposed to simian immunodeficiency virus". Emerging Infectious Diseases.
146. (2001). "Serial human passage of simian immunodeficiency virus by unsterile injections and the emergence of epidemic human immunodeficiency virus in Africa". Philosophical Transactions of the Royal Society B.
147. (2008). "Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960". Nature.
148. (2010). "High GUD incidence in the early 20th century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains". PLOS ONE.
149. (1998). "An African HIV-1 Sequence from 1959 and Implications for the Origin of the epidemic". Nature.
150. (October 28, 1987). "Boy's 1969 death suggests AIDS invaded U.S. several times". [[The New York Times]].
151. (January 2000). "Origin of HIV type 1 in colonial French Equatorial Africa?". AIDS Research and Human Retroviruses.
152. McNeil, Donald Jr.. (September 16, 2010). "Precursor to H.I.V. was in monkeys for millennia". [[The New York Times]].
153. (May 2009). "Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2". PLOS Computational Biology.
154. (May 18, 2020). "On this day". [[News & Record]].
155. (December 2017). "Mandell, Douglas, and Bennett's principles and practice of infectious diseases". Churchill Livingstone/Elsevier.
156. (2006). "Pneumocystis pneumonia—Los Angeles. 1981". American Journal of Public Health.
157. (October 1981). "Disseminated Kaposi's sarcoma syndrome in young homosexual men". Journal of the American Academy of Dermatology.
158. (September 1981). "Kaposi's sarcoma in homosexual men — a report of eight cases". The Lancet.
159. (December 2007). "Reverse transcription of the HIV-1 pandemic". The FASEB Journal.
160. (2000). "Encyclopedia of Microbiology". Elsevier.
161. Centers for Disease Control. (1982). "Persistent, generalized lymphadenopathy among homosexual males". [[Morbidity and Mortality Weekly Report]].
162. (1983). "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)". [[Science (journal).
163. Centers for Disease Control. (1982). "Opportunistic infections and Kaposi's sarcoma among Haitians in the United States". Morbidity and Mortality Weekly Report.
164. Altman LK. (May 11, 1982). "New homosexual disorder worries health officials". [[The New York Times]].
165. (1987). "AIDS and Syphilis: The Iconography of Disease". October.
166. (July 28, 2006). "Making Headway Under Hellacious Circumstances". [[American Association for the Advancement of Science]].
167. Kher U. (July 27, 1982). "A Name for the Plague".
168. Centers for Disease Control. (1982). "Update on acquired immune deficiency syndrome (AIDS)—United States". Morbidity and Mortality Weekly Report.
169. (1983). "Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)". [[Science (journal).
170. "The 2008 Nobel Prize in Physiology or Medicine - Press Release".
171. (30 May 1991). "GALLO ADMITS FRENCH DISCOVERED AIDS VIRUS". Chicago Tribune.
172. (2001). "Who's who in gay and lesbian history". Routledge.
173. Levy JA. (1984). "Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS". Science.
174. (1985). "Infection by the retrovirus associated with the acquired immunodeficiency syndrome". Annals of Internal Medicine.